CEP290 stereopure antisense oligonucleotide therapy (Wave Life Sciences)

N/A

Report date: 2025/01/26 17:52:41
NME

Base Information

Drug NameCEP290 stereopure antisense oligonucleotide therapy (Wave Life Sciences)
Drug Alias NameCEP290 Gene Inhibitor (Wave Life Sciences)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionCentrosomal protein of 290 kDa inhibitors
TargetsCentrosomal protein of 290 kDa
Therapy Area/IndicationsLeber Congenital Amaurosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesWave Life Sciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWave Life Sciences Ltd
Inactive CompaniesN/A
Active IndicationsLeber Congenital Amaurosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A